Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500616 | 0.86 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL5681855 | 0.80 | NPSR1 (0.59) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL711944 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL2711960 | 0.79 | KDM4E (0.50) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL30218684 | 0.79 | MASP2 (0.48) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL2360716 | 0.79 | MASP2 (0.48) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL5679579 | 0.79 | MAPT (0.57) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL18628731 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL666767 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL10325105 | 0.78 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112292370-A | Isoindolines as HDAC inhibitors | 瓦洛早期发现股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | NPBWR1 2624/4885KIF11 2336/4885KDM4E 223/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | NPBWR1 2819/4885KIF11 2147/4885KDM4E 204/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | NPBWR1 2624/4885KIF11 2336/4885KDM4E 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.